dideoxynucleosides (30) , phosphonoformate (36) , interferons (23) , dextran sulfate (31) , and recombinant soluble CD4 (39) , have demonstrated anti-HIV-1 activity in vitro. Of the compounds which have been evaluated, AZT is among the most potent agents against HIV-1 replication and has been an effective drug in the clinical treatment of patients with AIDS (15) , whereas 2',3'-dideoxyinosine and 2',3'-dideoxycytidine are presently under clinical evaluation. The clinical usefulness of AZT is limited by its toxicity (34) and the development of resistance to AZT by HIV-1 strains in patients undergoing long-term therapy (26) . In the search for meation of FLT into the cells, and the phosphorylation and intracellular pharmacokinetics of FLT and incorporation of FLT into DNA; the effects of FLT on the natural nucleotide pool sizes; and the pharmacokinetics of FLT in monkeys.
MATERIALS AND METHODS
Cells and virus. MT4 and MT2 cells (human T-cell leukemia lines), H9 cells (a human T-cell line), and human peripheral blood lymphocytes (PBL) were used. For PBL experiments, the cells were first stimulated for 48 h with phytohemagglutinin (PHA) (10 ,ug/ml) in RPMI 1640 medium containing 2 mM L-glutamine, 100 U of penicillin per ml, and 100 ,ug of streptomycin per ml and supplemented with 20% fetal calf serum. HIV-1 (human T-cell lymphotropic virus type IIIB strain) was obtained from R. Gallo (National Institutes of Health, Bethesda, Md.). Concentrated stocks of HIV-1 were obtained from cell-free supernatants of infected H9 cell cultures and frozen at -80°C until used. The 50% tissue culture infective dose (TCID50) per milliliter of the cell-free virus stocks was determined by endpoint titration with MT4 cells in 96-well microdilution plates. The TCID50s were calculated by the median-effect plot by using a computer program (10) . The AZT-resistant HIV-1 strains A018 J112-2 (predrug isolate) and A018 G910-6 (postdrug isolate), which were obtained from the AIDS Research and Reference Reagent Program of the National Institute of Allergy and Infectious Diseases, were propagated in MT2 cells by following the procedures as previously described (26) . Chemicals (38) . XTT prepared, neutralized with tri-n-octylamine in trichloro-trifluoroethane (Freon), and subjected to anion exchange (Partishere SAX-5, 12.5 by 0.4 cm) HPLC analysis at 45°C for determination of mono-, di-, and triphosphate levels as described by Cooney et al. (12) , with a linear gradient of 0.02 to 0.7 M KH2PO4 (pH 3.5) developed over 52 min at a flow rate of 2 ml/min. The A260 was monitored. For all analyses, the elution time of radioactive peaks was determined by comparison with authentic standards. The retention times for AZT, 3'-azido-3'-deoxythymidine-5'-monophosphate, 3'-azido-3'-deoxythymidine-5'-diphosphate, and 3'-azido-3'-deoxythymidine-5'-triphosphate (AZTTP) were 0.93, 5, 16.5, and 34 min, respectively; those for FLT, 3'-fluoro-3'-deoxythymidine-5'-monophosphate, 3 '-fluoro-3'-deoxythymidine-5' -diphosphate, and 3' -fluoro -3' -deoxythymidine-5'-triphosphate (FLTTP) 36, 1992 on November 6, 2017 by guest http://aac.asm.org/ Downloaded from cells and PBL was measured as described previously (11) . Whereas the supernatants of trichloroacetic acid extracts were subjected to studies of nucleotide levels and intracellular pharmacokinetic parameters, the acid-insoluble fractions were used for DNA incorporation studies. For the alkali stability studies, DNA was incubated with 0.5 N NaOH at 37°C overnight and then centrifuged. The radioactivity remaining in the pellets and the radioactivity in the supernatants were counted and compared with the control (without NaOH treatment). Determination of deoxynucleoside 5'-triphosphate pool sizes. Deoxynucleoside triphosphate pools were measured by the method of Garrett and Santi (18) , with the modifications that trichloroacetic acid instead of perchloric acid was used for the extraction and 5 M cyclohexyl ammonium chloride and 2 M glycerol were substituted for methylamine and rhamnose, as described by Hao et al. (19) . The Partisphere SAX-5 column was used for the HPLC analysis at 45°C, with a gradient elution from 0.02 to 0.7 M ammonium phosphate buffer, pH 3.5, over 52 min at 2 ml/min. The A260 was monitored.
Uptake and membrane transport of FLT (Fig. 3) . The incorporated radioactivity remained at similar levels between 30 min and 24 h after removal of the compounds (data not shown). The incorporation of [3H]FLT or [3H]AZT into the acid-insoluble DNA fraction in PHA-stimulated and non-PHA stimulated PBL was also studied. For FLT, 0.02-pmol and 0.18-pmol equivalents were incorporated in non-PHA-stimulated and PHAstimulated PBL, respectively. By contrast, 0.06-pmol and 1-pmol equivalents of AZT were incorporated into DNA of non-stimulated and PHA-stimulated PBL, respectively. Similar to the results from MT4 cells, the incorporated radioactivity of AZT and FLT was not decreased after removal of drug from the medium for up to 24 h (data not shown).
Alkali stability of FLT-, AZT-, or dThd-incorporated DNA was also studied. Compared with the dThd-incorporated DNA, overnight alkali incubation (0.5 N NaOH) of FLT-or AZT-incorporated DNA resulted in marked increases in the loss of radioactivity in the DNA precipitates. Hours Hours
FIG. 2. Elimination t112s of the total nucleotides (-NPS) and triphosphate after 12 h of exposure to [3H]FLT (A) or [3H]AZT (B) (1.8 JIM)
in PHA-stimulated human PBL. The tl2s given are the initial elimination tl2s (phase 1 (Fig. 4A and B) . The influx of [3H]AZT into HL-60 cells was linear for up to 120 s. However, NBMPR-P had little effect on the rate of [3H]AZT influx into the same cells under the same experimental conditions (Fig. 4C ). In addition, there were no permeation lag periods as for FLT or dThd in the presence of NBMPR-P. The transport inhibitor concentration-dependent effects on influxes of FLT, AZT, and dThd into HL-60 cells are shown in Fig. 5 . Consistent with the results from the time course experiments, NBMPR-P inhibited the influxes of FLT and dThd in a concentration-dependent manner up to 1 ,uM; a further increase in the NBMPR-P concentration (2 to Fig. 2 . The experimental conditions were the same as those described in the legend to Fig. 2 , except that a different batch of PBL (from different donors) was used. Although the absolute values of nucleotides formed are different, the elimination kinetics (4/2) are quite close to those presented in Fig. 2 . The results of total nucleotide and triphosphate formation in the presence (+PHA) and absence (-PHA) of PHA were 30-to 100-fold different. The values given are the averages from two experiments. The average variation from the mean was 14%. Hours of Exposure FLT from the gut after p.o. dosing was variable, with bioavailabilities of 140, 150, and 60% for monkeys J-153, J-185, and J-218, respectively, which were determined by a method described previously (35) .
Formation of FLT-glucuronide in monkey urine. The amounts of FLT, FLT-glucuronide, and unidentified FLT metabolites in urine of three monkeys after i.v. doses of 3 mg of [3H]FLT per kg were determined. The recoveries of the total radioactive doses after i.v. injection in two monkeys were 44 to 67% and 47 to 71% at 8 and 48 h, respectively. HPLC analysis showed that 40.8 to 60.5% of the total doses was identified as unchanged FLT in urine, with a retention time of 12.2 to 12.45 min. Of the total dose, 3.2 to 7.4% was identified as glucuronide-conjugated FLT, with a retention time of 7.5 to 8 min, and only about 3% of the total dose was found to be unidentified metabolites which contained four small peaks, with retention time ranging from 8. about 10% of the total FLT recovered. From specimens from the 48-h to the 168-h urine collection periods, only 1.6% of the total radioactive FLT three monkeys were identified as glucuronide-conjugated FLT during the 24-h collection period after dosing.
DISCUSSION
The main purpose of the present study was to compare the pharmacological properties of FLT with those of the most widely used anti-HIV-1 agent, AZT, under identical experimental conditions. The data presented here show that the dThd analog FLT is a potent inhibitor of HIV-1 replication in vitro, with no detectable inhibitory effect on the cell growth of cultured MT4 cells at many thousandfold its effective concentration for inhibiting HIV-1 replication. In terms of potency against HIV-1 replication and their selectivity indices in vitro, FLT is at least as potent as AZT and has a slightly better selectivity index. These results are in agreement with previously published data (4, 21, 29) . Furthermore, the incorporation of FLT into DNA of MT4 cells and human PBL is two-to eightfold less than that of AZT. These data suggest that FLT may be a more selective inhibitor of HIV-1 replication than AZT. The finding that an AZT-resistant HIV-1 strain is sensitive to FLT is consistent with data from an earlier report (33) . This lack of cross-resistance may be important given the development of resistance to AZT by HIV-1 strains from patients receiving prolonged AZT therapy (26, 33) .
The antiviral activity of nucleoside analogs may be dependent on multiple factors, such as the ability to form their corresponding 5'-triphosphate, the ability of the triphosphates to act as alternate substrate inhibitors for the target enzyme, the ability to disturb the endogenous pools of physiological deoxynucleotides, the intracellular pharmacokinetic behavior of the active metabolite, and the mechanism by which the nucleoside permeates the cell membrane. The intracellular concentrations of FLT'TP in MT4 cells, as well as in human PBL, are severalfold higher than those of AZTTrP. We and others (19) have found that FLT and AZT do not perturb endogenous dNTP levels at concentrations effective against HIV-1 in vitro and above expected therapeutic levels in plasma in vivo. Cheng et al. (9) reported that FLTTP competitively inhibited HIV-1 RT, with a Ki of 5 ,uM compared with a Ki of 13 ,uM for A.ZT`IT in a purified RT system with (rA)n(dT)n as template and [3H]dTTP as substrate. These and the present data suggest that the in vitro anti-HIV-1 activity of FLT, relative to that of AZT, may be due to enhanced intracellular metabolism of FLT to form its triphosphate despite lower total drug nucleotide concentrations.
High concentrations of FLT resulted in decreased dTTP and dCTP pool sizes. This decreased the dCTP pool size is unexpected since the allosteric regulation of dCTP is inhibited by dTTP. dCTP would be increased if FLTTP is competitive, with dTTP leading to increased dCTP as a result of dTTP inhibitory feedback release. The reasons for this decrease in dCTP pool size are unknown. Furman et al.
reported that AZT (50 p,M) also reduced the dCTP pools (17) . However, Frick et al. later found that cells treated with AZT resulted in an increase in dCTP pools (16) . These differences may be in part due to the different experimental conditions and the methods used for the quantitation of intracellular nucleotide pools (16, 20) . Cox and Harmenberg (13) previously reported that FLT at 0.1 ,uM reduced the dTTP pool by almost one half in CEM cells. This is consistent with the results presented here for higher FLT concentrations. Reduction in the endogenous pool size of dTTP by exposure of cells to high concentrations of FLT may play a role in the cytotoxicity of FLT. A reduction in the level of d'lTP, a competitive substrate for FLTTP, would facilitate the binding of FLTTP to HIV-1 RT and the host cellular DNA polymerases. This was supported by the observation that three times more FL1TT7P and AZ1TP were formed in cells pretreated with 5-fluoro-2'-deoxyuridine, a thymidylate synthase inhibitor, as a result of decreased competition by dThd triphosphate (13) .
For both FLT and AZT, the intracellular elimination of the total nucleotides as well as triphosphates followed biphasic kinetics in both MT4 cells and human PBL. For AZTNPs and FLTNPs, the tl2s at phase 1 and phase 2 were comparable. The initial retention t1,2 of FLTTP in PHA-stimulated PBL is 2.4-fold longer than that of AZTTP. In the present study, the phosphorylated nucleotide levels, expressed as picomoles per 106 cells, are approximately equivalent to micromolar units for intracellular concentration since a 109-lymphocyte pellet occupies a volume of about 1 ml. The absolute levels of FLTTP (0.58 to 0.24 p,M) were severalfold higher than those of AZT'P (0.13 to 0.10 FM) throughout 0 to 6 h of the elimination period and remained higher intra-VOL. 36, 1992 on November 6, 2017 by guest http://aac.asm.org/ Downloaded from cellularly during the 6-to 24-h period of the elimination phase (0.24 to 0.06 p,M versus 0.10 to 0.06 ,uM). These intracellular concentrations of FLTTP are higher than the 50% inhibitory concentration for RT (0.05 ,uM in purified enzyme system) during the 0-to 24-h period of the elimination phase. Furthermore, the longer intracellular tl2s (especially at phase 2) of FLT nucleotides compared with the short t1/2 (1.2 h) of the nucleoside in the plasma of monkeys may have important implications in the design of a dosing schedule for clinical trials.
We observed that total levels of FLT nucleotides formed were lower than those for AZT, although the FLTTP levels were higher than AZTTP levels in both MT4 cells and human PBL. Our data confirm those of Matthes et al., who found that FLT is well phosphorylated to 5'-triphosphates in various relevant cell lines to fairly stable levels without accumulation of 5'-monophosphates to the extent previously described for AZT (28) , and Cox and Harmenberg, who found that 10 times more FLTTP than AZTllP was formed in CEM cells during a 24-h incubation (13). Furman et al. (17) demonstrated that the second phosphorylation step for AZT was catalyzed by cellular dTMP kinase, which also catalyzed the rate-limiting step in the anabolism of AZT and its triphosphate. This was confirmed by other investigators who reported that the rate-limiting step in the formation of AZTTP was conversion of the monophosphate to diphosphate with a monophosphate accumulation (24) . Our results for AZT nucleotide distribution patterns support these observations, whereas results for FLT nucleotide distribution patterns indicate that the phosphorylation and/or catabolism of FLT may be different from that of AZT.
Our data for influxes of FLT and AZT into HL-60 cells indicated that these two structurally related nucleoside analogs permeate the membrane of HL-60 cells by different transport systems. FLT, like all of the physiological nucleosides and most of nucleoside analogs thus far investigated (44), appears to be dependent on a nucleoside transport system for its entry into cells, as evidenced by the blockage of this transport by the nucleoside transport inhibitor NBMPR-P. However, this inhibition of nucleoside transport showed two components. The initial complete inhibition was followed by a loss of inhibition when the time of exposure to NBMPR-P was increased. This observation indicated that the permeation of FLT into cells may be only partially dependent on a nucleoside transporter system and that other transport mechanisms, such as diffusion, may also be involved. The observation that AZT permeates the HL-60 cell membrane by a nucleoside transporter-independent system confirmed data in the previous report by Zimmerman et al. (44) . They suggested that AZT permeates into the human erythrocyte and lymphocyte membrane mainly by nonfacilitated diffusion and not via the nucleoside transporter. This difference of transporting across the cell membrane between FLT and AZT may largely result from the fact that AZT is more lipophilic than FLT (37, 44) and may contribute to differences in extracellular and intracellular pharmacokinetic behavior.
The elimination tj12 of FLT (1.19 h) in monkeys after i.v. dosing presented here (Table 4) is slightly longer than that of AZT (0.5 to 1 h) as reported by other investigators (6, 37) . The steady-state volume of distribution for FLT in the monkeys after i.v. dosing is greater than the volume of total body water, and FLT was eliminated at a moderate rate, with a total clearance of 0.66 liter/h, which accounts for about one-half of the hepatic and renal-blood flow rates. Basically, the pharmacokinetic parameters of FLT in cynomolgus monkeys after i.v. dosing presented here are well in agreement with those reported for rhesus monkeys (37) by Schinazi et al. The pharmacokinetic patterns of FLT after i.v. injection in rats as described by Boudinot et al. (7) are also quite comparable to those found with monkeys. However, the pharmacokinetic parameters of FLT after p.o. dosing were quite different from those reported by Schinazi et al. (37) , although both laboratories have found that the absorption bioavailability and peak time concentration of FLT after p.o. administration in monkeys were variable. This is not unexpected, since the absorption of the drug from the gastrointestinal tract involves multiple factors such as dose, differences in gastric emptying rates, enterohepatic recycling, and first-pass metabolism. Furthermore, the different monkey species used and the time period during which the animals fasted prior to initiation of the pharmacokinetic studies may also be contributing factors. In this study, the bioavailability of FLT after p.o. dosing was higher than 100% in two monkeys and 60% in one monkey. In our earlier studies, the bioavailability of FLT after p.o. dosing in cats was also found to be higher than 100% (data not shown). The above results indicate that p.o. administration is feasible. The variability in oral bioavailability in humans will need to be evaluated.
Glucuronidation is the primary metabolism for most nucleoside analogs, including AZT, in monkeys and humans (5, 6) . To our surprise, only a small portion of glucuronideconjugated FLT (3 to 7.3% of total dose) was detected in monkey urine, and the ratio of glucuronide-conjugated FLT/ FLT was only 0.1. Total metabolites in urine were only 7 to 11% of the total dose. This observation is quite different from that published by Schinazi et al. (37) , who found that the ratio of glucuronide-conjugated FLT/FLT was 1.45, which was similar to the ratio of glucuronide-conjugated AZT/AZT (1.5) . This discrepancy may be due to the different methods and experimental conditions used (e.g., we used 3 or 6.25 mg/kg in cynomolgus monkeys, whereas others [37] used 60 mg/kg in rhesus monkeys). Our results indicate that FLT is excreted in urine predominantly as unchanged drug, and the lower degree of glucuronidation of FLT relative to AZT may lead to longer tl/2s in plasma in vivo.
We observed that FLT or AZT incorporated into the acid-insoluble DNA fraction of MT4 cells and human PBL remained at similar levels for 24 h after removal of the drug and that FLT-or AZT-incorporated DNA is labile with alkali treatment. These data suggest that the 3'-terminal DNA labeling by these nucleoside analogs (42) is not readily removed under normal conditions. Results of reports correlating incorporation of AZT into DNA and toxicity are variable (40, 42) . The relationship between the incorporation of FLT into DNA and toxicity for human bone marrow progenitor cells is worthy of further investigation.
